NOVO — Januar 2025
-
Fra MW "Novo Nordisk har fået finjusteret kursmålet hos investeringsbanken Carnegie, der dog fortsat ser stort potentiale i den danske medicinalaktie.
Kursmålet er nu 1024 kr. mod tidligere 1090 kr., viser data fra Bloomberg News.
Anbefalingen "køb" gentages."
-
Det her jeg mener pauly….grønt overalt, men Novo bliver “trykket” ned igen
-
Redefine 2 data skulle være på trapperne
-
Novo Nordisk Says New Phase III Trial Of Obesity Drug Candidate Cagrisema Launching On Feb. 10 Will Study Long-Term Efficacy Of Cagrisema, Part Of Redefine Series; Says It Has Not Yet Posted Details About New Cagrisema Trial To Test Weight Loss In Obesity Patients Planned After Late-Stage Trial Data In December
-
Servicemeddelelse: Beklager enkelte udfald på sitet. Vi er ved at konfigurere vores firewalls efter hidsige hackerangreb de seneste dage. Hoveddelen af dette arbejde prøver vi at færdiggøre lørdag. Mvh Helge
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind